Mood disorder
Therapeutic area
Psychiatry
Rare disease
No
- Definition
- A cognitive disorder a disturbance in which the person's mood is hypothesized to be the main underlying feature.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Mood disorder
- Therapeutic area
- Psychiatry
- mood disorder
- episodic mood disorder
- Severity
- Mild
- Neurology
- Psychiatry
- MONDO ID
- MONDO:0005371
- Parent condition
- MONDO:0005084
Related records
Broader conditions (9)
- Brain disorder
- Central nervous system disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Human disease
- Mental disorder
- Nervous system disorder
- Psychiatric disorder
Narrower conditions (25)
- Atypical depressive disorder
- Bipolar depression
- Bipolar disorder
- Bipolar I disorder
- Bipolar II disorder
- Cyclothymic disorder
- Depressive disorder
- Dysthymic disorder
- Endogenous depression
- Major affective disorder 1
- Major affective disorder 2
- Major affective disorder 3
- Major affective disorder 4
- Major affective disorder 5
- Major affective disorder 6
- Major affective disorder 7
- Major affective disorder 8
- Major affective disorder 9
- Major depressive disorder
- Manic bipolar affective disorder
Trials (546)
- "Art Therapy" in Acute Psychiatry
- 7T Amygdala and Citalopram Study
- A Bioequivalence Study of 15 mg ER OROS Paliperidone
- A Clinical Study to Assess the Effect of a Dietary Supplement on Menstrual Cycle Symptoms
- A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder
- A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression
- A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression
- A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder
- A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth
- A Controlled Trial of Patient Centered Telepsychiatry Interventions
- A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
- A Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide
- A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone
- A Family Depression Prevention Program
- A Family Intervention for Adolescent Problem Behavior (AKA Project Alliance 2)
- A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder
- A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
- A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers
- A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder
- A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR
Approved drugs (1)
- Bupropion hydrochloride
Drugs in development (36)
- Adatanserin Phase 2
- Amantadine Phase 1
- Amantadine hydrochloride Phase 1
- Amesergide Phase 2
- Amibegron Phase 3
- Amitifadine Phase 2
- Chlorophenylpiperazine Phase 2
- CX-157 Phase 2
- Dacinostat Phase 3
- Dasotraline Phase 3
- Dipraglurant Phase 2
- Divalproex sodium Phase 2
- DU 125530 Phase 2
- Elzasonan hydrochloride Phase 2
- Epoetin beta Phase 2
- Ergocalciferol Early phase 1
- Haloperidol Phase 2
- Lamotrigine Phase 3
- Litoxetine Phase 3
- Naluzotan Phase 2
Other linked drugs (2)
- Flibanserin
- Lithium